Immunology & allergy
Immune system & allergy clinical trials
Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We’re tracking 6,064 recruiting studies in this area right now.
By phase
- Not applicable3,004
- Phase 21,060
- Phase 1794
- Phase 1/Phase 2439
- Phase 3436
- Phase 4233
- Phase 2/Phase 398
Top conditions
- Multiple Myeloma328
- Multiple Sclerosis328
- Asthma194
- Lymphoma178
- Rheumatoid Arthritis131
- Type 1 Diabetes131
- Atopic Dermatitis124
- Systemic Lupus Erythematosus119
- Acute Lymphoblastic Leukemia118
- HIV Infections106
- Chronic Lymphocytic Leukemia96
- Autoimmune Diseases78
- Follicular Lymphoma70
- Rheumatoid Arthritis (RA)68
- Hodgkin Lymphoma64
- Diabetes Mellitus, Type 163
- Leukemia63
- Type 1 Diabetes Mellitus63
Leading sponsors
- National Institute of Allergy and Infectious Diseases (NIAID)97
- Institute of Hematology & Blood Diseases Hospital, China85
- National Cancer Institute (NCI)74
- Assistance Publique - Hôpitaux de Paris65
- AstraZeneca64
- M.D. Anderson Cancer Center58
- Novartis Pharmaceuticals58
- Mayo Clinic50
- City of Hope Medical Center48
- Memorial Sloan Kettering Cancer Center45
Where studies are running
- California498
- Maryland199
- Alabama178
- Florida152
- Arizona149
- Massachusetts117
- New York116
- Texas112
- Illinois82
- Colorado81
Recruiting studies6,064 total
- NCT07003295RecruitingPhase 2
Glofitamab for mantle cell lymphoma that returned after CAR-T
This trial tests a new drug, glofitamab, for mantle cell lymphoma that came back or didn’t respond after CAR-T cell therapy. It aims to see if glofitamab can shrink or control the lymphoma.
Duarte, CaliforniaAges 18 years+ - NCT07005713RecruitingPhase 1
Study of tacabrutideg for chronic spontaneous urticaria
This trial tests a new oral medication called tacabrutideg (BGB-16673) for chronic spontaneous urticaria, a condition with frequent hives and itching. It aims to see how safe it is and how well it works, possibly offering a new option for people who still have symptoms despite antihistamines.
Beijing, Beijing MunicipalityAges 18–70 - NCT07003425RecruitingPhase 2
Long-term safety and effectiveness of APG777 for eczema
This study looks at the long-term safety and how well APG777 works for people with eczema (atopic dermatitis). It is for people who have already completed treatment with APG777 in an earlier study and may benefit from continuing it.
Fountain Valley, CaliforniaAges 18 years+ - NCT07011056RecruitingPhase 3
Study of a new drug for diffuse large B-cell lymphoma
This trial tests a new drug called Purinostat Mesylate for people with diffuse large B-cell lymphoma (a type of blood cancer) whose cancer has come back or not responded after at least two prior treatments. It aims to see if the drug can help shrink or control the cancer.
Chengdu, SichuanAges 18 years+ - NCT07007962RecruitingPhase 3
Oral pill for immune thrombocytopenia after first treatment fails
This trial tests an oral medicine called rilzabrutinib for adults with immune thrombocytopenia (ITP) whose first treatment stopped working or who need steroids long-term. The goal is to see if it helps raise platelet counts and reduce bleeding risk.
Clovis, CaliforniaAges 18 years+ - NCT07010835RecruitingPhase 1/Phase 2
Study of YK012 for moderate to severe lupus
This trial tests a new drug, YK012, for people with moderate to severe lupus. It aims to see if the drug can reduce disease activity and improve symptoms.
Beijing, Beijing MunicipalityAges 18–75 - NCT07011966Recruiting
A breathing therapy for insomnia
This trial tests a new type of breathing therapy (ASV) for people with insomnia. It looks at whether the therapy can help you fall asleep and stay asleep better.
Detroit, MichiganAges 18 years+ - NCT07011524RecruitingPhase 2
Study of CM512 injection for moderate-to-severe asthma
This trial tests a new injection, CM512, for people with moderate-to-severe asthma that is not well controlled with current inhalers. It aims to see if the treatment can reduce asthma attacks and improve symptom control.
Guangzhou, GuangdongAges 18–75 - NCT07011043RecruitingPhase 1
Study of budoprutug for lupus
This trial tests an investigational drug called budoprutug for people with active systemic lupus erythematosus (SLE) that has not improved after at least two previous treatments. The goal is to see if it can help control lupus symptoms.
Allen, TexasAges 18–65 - NCT06797024Recruiting
Study of JY231 injection for tough nerve immune disorders
This trial tests a new injection called JY231 for people with certain hard-to-treat nerve and immune disorders that haven't improved with standard treatments. It aims to see if this experimental therapy can help control the disease when other options have failed.
Wuhan, HubeiAges 18–75 - NCT07006506RecruitingPhase 2
Belumosudil to prevent graft-versus-host disease after transplant
This study tests whether a drug called belumosudil can help prevent graft-versus-host disease (GVHD) after a stem cell transplant. It is for people who have had a recent transplant and are at risk for GVHD.
Basking Ridge, New JerseyAges 18 years+ - NCT07011810RecruitingPhase 2
Axatilimab for sclerotic chronic graft-versus-host disease
This study tests a new drug called axatilimab for people with a specific type of chronic graft-versus-host disease (cGVHD) that causes hardening or thickening of the skin or joints. cGVHD is a complication after a stem cell transplant where the donor's immune cells attack your body. The study aims to see if axatilimab can improve these sclerotic symptoms. If you have this condition and it was recently diagnosed (within the last year), you might qualify to participate.
Tampa, FloridaAges 18 years+ - NCT07013435Recruiting
Resilience training for lymphoma survivors
This study tests a program to help lymphoma survivors build resilience and improve long-term quality of life after treatment. It's a behavioral intervention, not a drug trial, that focuses on coping and well-being.
Boston, MassachusettsAges 18 years+ - NCT07011238Recruiting
Memory B cells and anti-HLA antibodies in kidney transplant patients
This study looks at how memory B cells (a type of immune cell) relate to antibodies against HLA in people waiting for a kidney transplant. It aims to better understand immune responses, which could help improve transplant matching and outcomes.
RouenAges 18 years+ - NCT07010302RecruitingPhase 4
Comparing medications for NMOSD
This trial compares several medications to see which works best for NMOSD, an autoimmune disease that can cause vision loss and paralysis. You must have a specific antibody (AQP4-IgG) to join.
Boston, MassachusettsAges 18 years+ - NCT07013110RecruitingPhase 2
AI-guided precision therapy for active rheumatoid arthritis
This study tests a new, AI-powered treatment approach for rheumatoid arthritis. It's for people with active disease who haven't used certain biologic or targeted therapies in the last 6 months.
SingaporeAges 21 years+ - NCT07012928Recruiting
Study of immune responses in eosinophilic esophagitis patients
This study looks at how the immune system and the esophageal barrier function in people with eosinophilic esophagitis (EoE) compared to those without. It involves taking biopsies during an upper endoscopy to understand the disease better. The results may help improve treatments for EoE.
Amsterdam, North HollandAges 18–75 - NCT07011147Recruiting
Real-world test of automated insulin delivery in primary care
This study tests if an automated insulin delivery system (the iLet bionic pancreas) works well in real-world primary care settings for people with type 1 or type 2 diabetes. It aims to see if this technology can help manage blood sugar more easily.
Aurora, ColoradoAges 18–89 - NCT07011875Enrolling by invitation
Physical activity and period pain in women with MS
This study looks at how physical activity levels affect period pain, menstrual symptoms, and emotional well-being in women with multiple sclerosis. It aims to find out if being more active can help with these issues.
Karabük, Karabük ProvinceAges 18–55 - NCT07012447RecruitingPhase 2
Venetoclax with azacytidine for newly diagnosed T-cell leukemia
This trial tests a combination of venetoclax and azacytidine for people with certain types of T-cell acute lymphoblastic leukemia (T-ALL) that haven't been treated yet. It focuses on cases with specific genetic changes and aims to see if this drug pair can help control the disease.
Suzhou, JiangsuAges 14 years+ - NCT07009002RecruitingPhase 1/Phase 2
Modified CAR-T cell therapy for relapsed B-cell lymphoma
This study tests a new kind of CAR-T cell therapy for people with certain types of B-cell lymphoma that have come back or not improved after standard treatments. The CAR-T cells have been modified to turn off two genes (BCOR and ZC3H12) to make them work better against the cancer.
Beijing, Beijing MunicipalityAges 18–70 - NCT07006272Recruiting
Closed-loop pump vs islet transplant for unstable type 1 diabetes
This study compares two advanced treatments for type 1 diabetes that is hard to control: a closed-loop insulin pump system (which automatically adjusts insulin) versus islet cell transplantation (which replaces the cells that make insulin). It is for people whose blood sugar stays very unstable despite using the best current therapies.
Lyon, Auvergne-Rhône-AlpesAges 18 years+ - NCT07010250Recruiting
Kidney Energy Use and Scarring in ANCA Vasculitis
This study looks at how kidney cells use energy and how that leads to scarring in people with ANCA vasculitis. It compares findings with people who have other kidney diseases to better understand and possibly treat kidney damage.
ParisAges 18–90 - NCT07013565RecruitingPhase 2
Chemoimmunotherapy for ALK+ ALCL that has come back
This trial tests a combination of chemotherapy and immunotherapy for children and adults with a type of lymphoma called ALK-positive anaplastic large cell lymphoma that has returned or not responded to previous treatment. The goal is to see if this new approach can help control the disease.
Valhalla, New YorkAges 1–39
Common questions
- How many immune system & allergy clinical trials are recruiting?
- Clin2 is tracking 6,064 recruiting immunology & allergy studies from the U.S. registry right now, out of 9,178 we cover in this area in total.
- What does “Immune system & allergy” cover here?
- Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We group each study into immune system & allergy based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a immune system & allergy trial near me?
- Use the search to filter immune system & allergy studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.